Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune
Go back to Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune| (NASDAQ: SVRA) | Delayed: 5.70 +0.20 (3.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.50 | 52 Week High | $ | |||
| Open | $5.59 | 52 Week Low | $ | |||
| Day High | $5.79 | P/E | N/A | |||
| Day Low | $5.50 | EPS | $ | |||
| Volume | 1,963,020 | |||||
